Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

3.490 -0.090 (-2.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 638,203
Open 3.570
Bid (Size) 4.030 (2)
Ask (Size) 4.120 (3)
Prev. Close 3.580
Today's Range 3.490 - 3.620
52wk Range 1.280 - 4.650
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire

Performance

YTD
+144.06%
+144.06%
1 Month
-1.97%
-1.97%
3 Month
+27.37%
+27.37%
6 Month
-7.18%
-7.18%
1 Year
+162.41%
+162.41%

More News

Read More
Insights into ChromaDex's Upcoming Earnings
Via Benzinga
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From ChromaDex Corporation
Via Business Wire
CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024
Via InvestorPlace
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in the 17th Annual LD Micro Main Event
From ChromaDex Corporation
Via Business Wire
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
From ChromaDex Corporation
Via Business Wire
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
From ChromaDex Corporation
Via Business Wire
ChromaDex to Join Russell 2000® Index
From ChromaDex Corporation
Via Business Wire
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
From ChromaDex Corporation
Via Business Wire
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.